Study objectives-To examine equity in the health care system with regard to cancer patient care by estimating the level of systematic regional variation in cancer survival in the Nordic countries. Specifically, those cancer sites which exhibit high levels ofsystematic regional variation in survival and hence inequity were identified. Estimating the reduction in cancer deaths which could be achieved by eliminating this variation so that everyone receives effective care will provide a readily interpretable measure of the amount of systematic regional variation. A comprehensive analysis ofregional variation in survival has not previously been conducted so appropriate statistical methodology must be developed. Setting and participants-All those aged 0-90 years who had been diagnosed with at least one of 12 common malignant neoplasms between 1977 and 1992 in Denmark, Finland, Norway, and Sweden. Design-A separate analysis was conducted for each country. Regression models for the relative survival ratio were used to estimate the relative risk of excess mortality attributable to cancer in each region after correcting for age and sex. An estimate of the amount of systematic regional variation in survival was obtained by subtracting the estimated expected random variation from the observed regional variation. An estimate was then made of the potential reduction in the number of cancer deaths for 2008-12 if regional variation in survival were eliminated so that everyone received the same level of effective care. Main results-Between 2008 and 2012, an estimated 2.5% of deaths from cancers in the 12 sites studied could be prevented by eliminating regional variation in survival. The percentage of potentially avoidable deaths did not depend on country or sex but it did depend on cancer site. There was no relationship between the level of regional variation in a given country and the level of survival. The cancer sites for which the greatest percentage savings could be achieved were melanoma (11%) and cervix uteri (6%). The sites for which the highest number of deaths could be prevented were prostate, colon, melanoma, and breast.
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Conclusions-This methodology showed a small amount of systematic regional variation in cancer survival in the Nordic countries. The cancer sites with high levels of regional variation identified are potential targets for cancer control programmes.
(J Epidemiol Community Health 1997;51:289-298) Previous components of the Nordic collaborative project "Cancer in the Nordic countries in the years 1990, 2000 and 2010" (CiN) have predicted cancer incidence and mortality up to the year 2010.'2 In the current project we examine regional differences in survival within Denmark, Finland, Norway, and Sweden and estimate the potential saving in mortality which could be achieved by eliminating systematic regional variation in cancer patient survival such that everyone receives effective care.
The analysis of geographic variation is a popular methodology in health services research although the statistical methodology for such analyses has not been fully developed. "4 Most methods have been developed for the study of regional variation in rates, and have been applied to hospital admission rates, surgery rates, and in the field of cancer epidemiology, incidence, and mortality rates. [5] [6] [7] [8] [9] The most appropriate methods for our purposes have focused on answering the question: Is there more variation than can be explained by random factors and, if so, what is the size ofthe systematic variation? 5 We have developed a similar methodology for studying regional variation in survival, although the methodology is complicated by the fact that survival is mathematically more difficult to estimate than incidence or mortality rates.
After estimating the level of systematic regional variation in cancer survival, the potential reduction in cancer mortality which could be achieved in the years 2008-12 by eliminating this variation is estimated. Any overall reduction in mortality is brought about by improving the survival in those regions with low survival such that survival rates in all regions are equivalent to what would be expected if everyone received the same level of effective care. This reduction in mortality is additional to any reduction (or increase) in mortality due to trends in survival brought about by other factors.
The Nordic countries consist of Denmark, Finland, Iceland, Norway, and Sweden. The population of Iceland (250 000) is too small to facilitate a regional analysis so this study is restricted to the other four countries. We have taken the liberty of referring to these four countries as the Nordic countries.
Cancer 
REGIONS
The regions had to be large enough to allow accurate estimation of survival, yet small enough to reflect regional differences. Regions were defined using pre-existing administrative borders and consisted of 22 health care districts in Finland, 24 counties (lan) in Sweden, 16 counties (amter) in Denmark, and 19 counties (fylker) in Norway. The average regional populations were 226, 359, 321, and 226 thousand, respectively. It could be argued that it is scientifically more valid to define the regions such that they are homogeneous with respect to demographic or geographic characteristics which are of direct interest (such as socioeconomic status or some measure of access to health care). However, any future action which may be taken to reduce regional variation will require action by the regional health authorities, thus making it perhaps more appropriate to use these administratively defined regions.
EXCLUSIONS
Some cases were excluded from the analysis in order to obtain a more uniform material, primarily across regions within each country, but also across the different countries (table 2) . Reasons for exclusion were region of residence information not available, age at diagnosis greater than 90 years, diagnosis first made at autopsy, and information available from death certificate only (DCO). The survival time will be zero when the diagnosis is first made at autopsy or on the basis of death certificate only. When a registry receives a death notification for a patient (or tumour) which was not previously known to the registry, the registry contacts the appropriate hospital or physician in an attempt to ascertain the true date of diagnosis. Sometimes it is not possible to ascertain the true date of diagnosis and it is these cases which were excluded. When multiple primary tumours were registered in the same site for the same person, only information relating to the first tumour was included in the analysis. Multiple primary tumours in different sites were included independently in each site, provided other selection criteria were met.
For the Danish material, 5473 cases were excluded due to the diagnosis being first made at autopsy. An additional 6267 cases where only information from the autopsy report was available were excluded and are also reported in this category. The true diagnosis date for these 6267 cases may have been earlier but no additional information is available. The regional distribution ofthe excluded cases from each country were examined for systematic patterns which may introduce biases. The analysis was also repeated without excluding any cases as a means of testing the sensitivity of the results to the exclusions.
Statistical methods
The methodology developed for the current study of regional variation in survival can be described in three broad steps:
* Step 1-estimate survival for each region by modelling relative survival as a function of relevant predictor variables (age, sex, and region) for each cancer site * Step 2-estimate the amount of systematic (as opposed to random) regional variation in survival * Step 3-estimate the reduction in mortality which could be achieved ifthis variation were eliminated such that everyone receives the same level of effective care
Statistical models for relative survival analysis (step 1) are reasonably well developed, although little research has been conducted on methods for studying regional variation in survival (step 2). We have developed methods for examining regional variation in survival which have been applied in the current study.
STEP 1: MODEL FITTING
The analysis of survival from population based cancer registries with long term follow up is often performed using relative survival analysis. [18] [19] [20] We used the regression model developed by Hakulinen and Tenkanen,2' which models the total mortality (number of deaths divided by the person-time at risk) for persons diagnosed with cancer, ,u, as the sum of the known baseline mortality, p*, and the excess mortality due to a diagnosis of cancer, v. That is,
The subscripts indicate that the excess mortality of the patients (and hence their total mortality) depends on region (r), age (i), sex (s), and follow up interval (j). The baseline mortality depends on age, sex, and possibly region. The model was fitted individually to each of the 12 cancer sites in each of the four countries using the predictor variables region, age, sex, and an age by follow up interaction term (for the first five years of follow up only). The age variable contained three levels and was defined separately for each site. Each region was represented by a dummy variable in the regression model and an estimate of the relative risk of excess mortality due to cancer was obtained for each region. The age by follow up interaction term was required in order to obtain an acceptable fit to the data and indicates that the age specific hazards are non-proportional for the first five years of follow up.
The excess mortality component is assumed to be a multiplicative function of the covariates, such that Vi =ep(B reg + #B age + # sex + fl ige. ful)) 2 v,,:--. e p l i(2)
The individual model parameters (the fl's)
are interpreted as log relative risks of excess mortality due to cancer. As such, the relative risk of excess mortality due to cancer for residents of region r is given by RRr= exp(flr),
where the superscript reg has been omitted for simplicity. Mortality after t years of follow up, ji (t), is directly related to the survival rate S(t) through S(t) = exp [ -p (t) ]. The annual (interval specific) relative survival ratio for follow up interval j (and other covariates at levels r, i, and s) is given by r,jsj = exp( V,i,j)
Estimated regioR specific relative risks for Sweden, given by RR,= exp(,Br), where fr is the estimate for frs are presented in figure 1 as an example. A relative risk of 1.4 for a given region indicates that the risk of death due to the cancer in question is 1.4 times higher in that region than it is according to the average of all region specific excess mortalities. Each relative risk represents the ratio of the risks of cancer mortality after correcting for mortality due to other causes.
EXPECTED SURVIVAL
The relative survival ratio (also called the relative survival rate) at time t is the ratio of the observed survival of the cases to the expected survival for a comparable group in the general population. That is, r(t) = S(t)/S*(t), where S(t)=exp[-,u(t)] and S*(t)=exp[-,u*(t)].
Hence for the current model (1), we have r
, where r(t), ,u(t), ,u*(t), and v(t) are assumed to be constant for all values of t within each annual follow up intervalj and subscripts for the other covariates are omitted. When conducting a relative survival analysis, it is standard practice to estimate the expected survival rate S*(t) using age/sex specific mortality tables for the entire (nationwide) population. We would not expect the baseline mortality to be identical in all regions, so using nationwide life tables to estimate the expected survival will create bias. This bias is not of great concern when analysing nationwide data but may be important when we wish to estimate survival in individual regions or social class groups.
In order to study the effect of this bias, we calculated expected survival for the Finnish and Swedish material using region specific population life tables. In addition, we also estimated the expected survival for Finland using The estimates presented in figure 1 are unbiased estimates of the effect of living in each region and, like all estimates, are subject to random variation. For any given cancer site in figure 1 , it is possible that all of the observed variation among the region specific estimates is due to random variation, or it may be due to a combination of random variation and systematic differences in relative survival between the regions. It is possible to estimate the magnitude ofthe expected random variation, which depends on the number of cases and the survival rate. We developed an estimator V to estimate the magnitude of the systematic regional variation in survival by subtracting the estimated random variation from the observed variation in the estimates bl, ..., b, An appendix contains mathematical details of V, which is an estimator for p_ I (flr wf)2 r=l the variance of the ensemble of true regional effects. The value of Vwill be zero (or negative) if no systematic regional variation in survival exists and will increase in magnitude as the level of systematic variation increases. As was noted earlier, the estimated region specific relative risks presented in figure 1 are subject to both systematic and random variation. It is possible to calculate new estimates, so called second stage estimates (or shrinkage estimates), which differ solely due to systematic regional variation. That is, the estimates are adjusted to remove the effect of random variation. Second stage estimates were calculated by shrinking the crude relative risks towards the mean value (RR= 1) such that the amount of variation in the second stage estimates was equal to the estimated level of systematic regional We can use V to identify those cancer sites that exhibit systematic regional variation (the larger the value of V, the larger the systematic variation), but it is difficult to grasp the practical implications ofa given value of V By estimating the number of deaths "saved" by eliminating any regional variation in survival, we are able to present results with a more concrete interpretation. The number of cancer deaths (deaths attributable to cancer) in an interval is defined as the number of deaths in the interval minus the number of expected deaths according to mortality in a comparable group in the general population. We define the number of deaths "saved" by removing regional variation in survival as the reduction in the number of cancer deaths during the first 10 years of follow up (15 years for breast cancer). The longer time frame was used for breast cancer because a significant number of breast cancer deaths occur in the period 10-15 years after diagnosis. 24 Applying equations (2) and (3) to the estimated parameters from the regression model, it is a simple matter to estimate the relative survival ratio and the predicted number of deaths due to cancer for any combination of age, sex, and follow up year. The number of cancer deaths across all regions in follow up interval j (and given levels of age and sex) is then defined as the number of deaths in the interval minus the number of expected deaths according to mortality in a comparable group in the general population and is given by (4) where rj is the (model based) interval specific annual relative survival ratio (for given levels of age and sex), lj is the number alive at the start of follow up interval j, and p*' is the expected survival probability, taken from age/ sex specific population life tables. The number of cancer deaths was calculated for each follow up year and summed across the first 10 follow up years (15 for breast cancer) to obtain an estimate of the total number of cancer deaths for each country, age group, and sex. The number of cancer deaths was then recalculated under the assumption that any existing systematic regional variations were eliminated and relative survival in all regions was equivalent to what would be expected if everyone received the same level of effective care. The percentage difference between these two quantities is an estimate of the percentage of cancer deaths potentially "savable" by removing systematic regional variation in survival. A percentage equal to 0.0% indicates that there was no evidence of systematic regional variation in survival so no deaths can be saved by eliminating such variation. A percentage of, say, 1.6% indicates that eliminating regional variation in survival would save an estimated 1.6% of cancer deaths. In calculating these percentages, it was assumed that everyone could be followed up for at least 10 years (15 years for breast cancer) in order to eliminate any potential bias due to differential withdrawal patterns. namely professional and higher administration, lower administration, skilled workers, unskilled workers, farmers, and others. These social class categories were also used to construct the social class specific population life tables for Finland.
The aim of the social class analysis was to estimate the potential mortality savings if everyone had the same survival as the highest social class (professional and higher administration). The analysis proceeded identically to the regional analysis up to the stage where equation (5) was applied to estimate the excess cancer mortality under the assumption that every region received the same level of effective care (no regional variation in survival). The next step in the social class analysis was more straightforward, we re-estimated the number of deaths under the assumption that everyone had the same relative survival as the highest social class and estimated the potential savings in deaths under this assumption.
Results

EXPECTED MORTALITY
There were small differences in the estimated relative survival ratios (RSRs) calculated using the three different baseline mortality tables (nationwide, region specific, and social class specific) for calculating expected mortality. These differences were not large enough to cause concern about using nationwide life tables for calculating expected survival. For example, breast cancer is more common in the upper social classes so we would expect the estimated RSR for breast cancer using the social class life figure 2 . There was no evidence of systematic regional variation in survival for cancers of the larynx, cervix, and kidney as indicated by a negative value of V The second stage estimates of the relative risks for these sites are therefore all equal to one (fig 2) . Cancer of the larynx initially appeared to exhibit the highest level of regional variation in survival, but this was shown to be consistent with (or even less than) what we would expect due to random variation.
Systematic regional variation in cancer survival existed in each of the countries studied, although the level of variation differed according to site. All countries contained at least one site where there was no evidence of systematic regional variation. There were only minor differences in the results for males and females. Eliminating regional variation in survival in all countries would save an estimated 5271 (2.5%) cancer deaths in the 12 study sites during the five year period (table 4) . The corresponding number of deaths was 1282 (2.1 %) for Denmark, 1185 (2.9%) for Finland, 724 (1.9%) for Norway, and 2079 (2.9%) for Sweden.
The sites in which the highest number of deaths could be saved are prostate, colon, melanoma, and breast (table 4). The largest percentage savings could be achieved for melanoma (11%) and cervix uteri (6%). Although the total percentage of savable deaths was similar for each country, there were differences between the countries within each site. No one country, however, was systematically higher or lower than the others. The differences 
Discussion
The study objective was to examine equity in the health system by estimating the magnitude of systematic regional and social class variation in cancer survival. The results indicate that systematic regional variation (and hence inequity) exists in each of the countries studied.
Results have been presented primarily in terms of the number of cancer deaths which could be saved by removing such variation. It is unlikely that regional variation in survival will be eliminated in the near future such that all regions obtain the "effective care"" relative survival ratio assumed in the calculations. This is not to say, however, that the assumed "effective care" relative survival ratio is an unreasonable goal, since it has already been achieved by some regions for every site. The estimated number of savable deaths provides a ready method of quantifying the amount of systematic variation, thereby enabling identification of those sites where cancer control programmes may be most effective. Cases were excluded from the analysis if the diagnosis was first made at autopsy or if information was available from DCO. DCO cases are not included in data maintained by the Swedish cancer registry so were excluded from all data in order to maintain comparability. The effect of DCO cases on survival is not well defined and requires an understanding ofthe mechanism by which these cases are generated.29 It is generally accepted that if the true diagnosis dates of all DCO cases were known, the survival time of these cases would be considerably less than that of the "non-DCO" cases. Pollock and Vickers30 showed this empirically by tracing the true diagnosis dates of DCO registered cases in south east England.
The percentage of DCO cases in a given region depends upon the effectiveness of diagnostic, detection, and reporting procedures and the effectiveness ofretrospective follow up (also called follow back) at the cancer registry. Regions with ineffective diagnostic, reporting, and retrospective follow up systems will generally have a higher proportion of DCO and autopsy cases (which have zero survival time) and a correspondingly lower proportion of cases with low survival times. Survival rates for such regions will be overestimated (compared to survival rates for other regions) if DCO and autopsy cases are excluded but underestimated if these cases are included in the analysis. The main issue, therefore, is not whether DCO and autopsy cases are included or excluded from an analysis but whether these cases are evenly distributed across regions. Examination of the regional distribution ofDCO and autopsy cases showed no evidence of regional heterogeneity. To test further the effect of excluding these cases, the data were analysed without exclusions (apart from those cases where region of residence was not known). The estimated level of regional variation did not depend on whether or not cases were excluded. There were differences in the DCO rates between the four countries (table 2) although this will not affect the results since the analysis was conducted separately for each country.
Neither stage of disease at diagnosis nor year of diagnosis were included in the regression model. Stage is, of course, an important predictor of survival for all cancers, but it is not, however, justifiable to adjust survival rates for stage if the aim is to study the effect of the health care system on cancer survival. 22 If we assume that stage depends mainly on diagnostic delay, stage is not a confounding factor but rather an outcome variable of interest (i.e. a chain in the causal link).
Year of diagnosis is a predictor of survival for many cancers but the amount of regional variation in survival is not heavily dependent on year of diagnosis. We fitted models containing predictor variables for year of diagnosis (two levels) and a year of diagnosis by region interaction term to all 12 sites for Finland and Sweden. As expected, year of diagnosis was statistically significant for nine of the 12 sites for both countries. It was not statistically significant for cancers of the larynx, lung, cervix uteri (Sweden), and corpus uteri (Finland).
The year by region interaction was significant in four of the 12 sites for each country, namely cancers of the stomach, colon, prostate, and kidney for Finland and cancers of the larynx, lung, female breast, and prostate for Sweden. Including these additional terms in the model had little effect of the estimates of regional variation, even for the sites where the year by region interaction term was significant. We decided to report the results using models without year of diagnosis as we wanted to minimise the number of strata in order to estimate the regional differences as efficiently as possible.
It must be noted that although the lack of regional variation in survival for a given cancer site is a positive indicator, it does not mean that survival cannot be improved. It is quite possible for a given country to have the lowest amount of regional variation in survival compared to other countries yet have the worst survival, or vice versa. The presence of regional variation is an indicator of possible inequity, which points towards a potential for improvement in survival. The absence of regional variation does not necessarily preclude the possibility of improving survival, but it may be more effective to initially focus on those cancers where regional variation exists.
The Nordic countries offer unique opportunities for conducting this type of research due to the high quality of the cancer registry data and the existence of civil registration systems which enable linking ofthe cancer registry database to obtain individual patient level information on education, occupation, and social class. This makes the Nordic countries an ideal platform for developing and testing the current methodology. The Nordic countries are justifiably proud of their health care systems, including the access to and quality of care available to all inhabitants. One concern at the start of this study was that we would not find any regional variation and would not be able to test the methodology properly, but this has not been the case.
The ability to study regional and social class variation in survival will greatly facilitate the evaluation of cancer control. The results from this study enable the identification of sites where variation, and hence possible inequity exists. These sites should be further studied in an effort to understand the underlying causes of the variation, followed by cancer control programmes to reduce the variation. The methodology developed for use in this study can be applied to future data in order to study changes in the level of regional variation over time.
